Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07493460 · ClinicalTrials.gov registry record · Phase 4
Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines
A Phase 4 study, sponsored by Washington University School of Medicine.
- Active
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
NCT07493460 is a Phase 4 study that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 25 participants.
The verdict
NCT07493460, a Phase 4 study, is active but no longer recruiting, sponsored by Washington University School of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
Study Summary
This study is being done to understand and measure how the immune system responds to and remembers different types of vaccines. To do this, four vaccines approved by the U.S. Food and Drug Administration (FDA) will be given simultaneously to participants. Participants will be volumteers who are healthy adults (18 years old or older) and willing to receive the yearly trivalent inactivated influenza vaccine (TIV), the tetanus, diphtheria, and acellular pertussis vaccine (Tdap), the nonvalent HPV (HPV) vaccine, hepatitis A virus (HAV) vaccine and undergo study procedures. Procedures will include: * medical history relevant to the study, including medications and vaccines received. * Vitals (blood pressure, pulse) and temperature * Height and weight. * Physical exams. * Receive the TIV, Tdap, HPV, and HAV vaccines. * Blood samples collected for immunologic tests and genetic analysis. * Donate bone marrow by needle aspiration at a maximum of seven visits. * Complete memory aid every evening for 7 days after vaccination Optional Procedures include: * Donate bone marrow core biopsies at the same visits * Ultrasound of lymph nodes and fine needle aspirates of lymph nodes in both arm pits at a maximum of eight separate visits There will be a screening visit and and a Day 1 where vaccinations will occur and subsequent visits at Day 8, Day 14, Day 29, Day 57, Day 121, Day 181, Day 366, Day 546, and Day 731. At each of these visits health status, vital signs and blood collection will occur. A bone marrow aspirate and lymph node aspirate will be collected at screening. The six additional bone marrow aspirates will be repeated at D29, D91, D181, D366, D546, and D731. The optional bone marrow core biopsy will also be repeated at that time. Up to seven separate visits will be scheduled for the follow-up lymph node aspirates (D29, D57, D91, D181, D366, D546, and D731) Study participation will be 24 months.
Interventions
- BIOLOGICAL trivalent inactivated influenza vaccine (TIV)
- BIOLOGICAL nonavalent HPV vaccine (HPV)
- BIOLOGICAL hepatitis A (HAV) vaccines
- BIOLOGICAL tetanus, diphtheria and acellular pertussis vaccine (Tdap)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2025-08-26 |
| Est. Completion | 2027-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07493460
The ClinicalTrials.gov registry entry for NCT07493460 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which trivalent inactivated influenza vaccine (TIV) is the first listed.
NCT07493460 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07493460 about?
NCT07493460 is a clinical study titled "Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines". This study is being done to understand and measure how the immune system responds to and remembers different types of vaccines. To do this, four vaccines approved by the U.S. Food and Drug Administration (FDA) will be given simultaneously to participants. Participants will be volumteers who are heal...
What is the current status of trial NCT07493460?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2025-08-26. Estimated completion is 2027-08.
What interventions are being tested in trial NCT07493460?
The interventions under investigation include: trivalent inactivated influenza vaccine (TIV) (BIOLOGICAL), nonavalent HPV vaccine (HPV) (BIOLOGICAL), hepatitis A (HAV) vaccines (BIOLOGICAL), tetanus, diphtheria and acellular pertussis vaccine (Tdap) (BIOLOGICAL).
Who is sponsoring clinical trial NCT07493460?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.